FDA Grants Breakthrough Status to Fingerstick Syphilis Test
The FDA has granted Breakthrough Device Designation to MedMira's Multiplo Complete Syphilis antibody test, a fingerstick test that detects treponemal and non-treponemal antibodies at once with no instrument. The designation speeds up FDA review. It is not a clearance to sell the test.
Edited and fact-checked by Stephen Sprague
Breakthrough status shortens the review line. It does not shorten the evidence the test still owes the FDA.
The FDA has granted breakthrough device status to a fingerstick syphilis test that needs no laboratory instrument.
MedMira, a diagnostics company based in Halifax, Nova Scotia, announced on November 17, 2026, that the FDA's Center for Devices and Radiological Health granted Breakthrough Device Designation to its Multiplo Complete Syphilis (TP/nTP) Antibody Test. The test reads a single fingerstick of whole blood and detects two classes of antibody at once, treponemal (TP) and non-treponemal (nTP), using the company's Rapid Vertical Flow technology.
The two antibody classes answer different clinical questions. Treponemal antibodies show that a person has been infected with the syphilis bacterium at some point. Non-treponemal antibodies track with active disease and treatment response. A standard workup usually splits those questions across separate laboratory tests, and results can take days. A single point-of-care read puts both answers in one visit.
The designation is a review status, not a market approval, and the company says so in its own release. Breakthrough status gives a device prioritized FDA interaction and an expedited review path. It does not clear the test for sale in the United States, and it does not remove any regulatory requirement. MedMira also said the FDA's Total Product Life Cycle Advisory Program team has invited the company to apply for its pilot program.
One piece of outside evidence exists so far. An independent laboratory evaluation of the test was published in 2026 in the Journal of the Association of Medical Microbiology and Infectious Disease Canada, and it confirmed the test's clinical performance in that evaluation setting. A laboratory evaluation is not a clearance trial, and it does not substitute for the FDA review the designation now speeds up.
The practical claim is about setting, not just speed. A laboratory syphilis workup needs instruments, trained staff, and a sample shipped or batched before anyone reads a result. MedMira's test needs a fingerstick and the kit itself. That difference decides whether a small clinic, an outreach team, or an emergency department can ask both antibody questions during the visit in front of them instead of booking a follow-up the patient may never attend.
What happens next is procedural. MedMira still has to complete its regulatory submission and win FDA clearance before any US clinic can buy the test. Until then, the honest summary is narrow. A promising fingerstick test just moved into the FDA's faster lane, and nothing about that lane changes what the test still has to prove.
Sources
- MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo Complete Syphilis (TP/nTP) Antibody Test - MedMira Inc. news release via ACCESS Newswire, November 17, 2026
- Faster Syphilis Detection Moves Closer to Market with New U.S. Approval - WSNext, November 17, 2026, reporting the 2026 independent laboratory evaluation in the Journal of the Association of Medical Microbiology and Infectious Disease Canada
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.